Short-term memory loss associated with rosuvastatin
Short-term memory loss associated with rosuvastatin
复制标题
DOI：
10.1592/phco.26.8.1190
复制
发表时间：
2006-08-01
期刊：
影响因子：
4.1
通讯作者：
Spina, Edoardo
中科院分区：
文献类型：
--
作者：
Galatti, Laura;Polimeni, Giovanni;Spina, Edoardo
文献中报告了与几种3-羟基-3-甲基戊二酰辅酶A还原酶抑制剂（他汀类药物）相关的记忆丧失和认知障碍，但我们未发现与瑞舒伐他汀相关的已发表病例报告。据我们所知，这是第一例报告的瑞舒伐他汀相关的短期记忆丧失病例。1例53岁白人男性高胆固醇血症患者在接受瑞舒伐他汀10 mg/天治疗后发生记忆丧失。患者无其他伴随疾病或药物治疗。瑞舒伐他汀停药后，神经精神不良反应逐渐消退，表明可能与药物相关。在接下来的一年里，患者仍然没有神经精神障碍。临床医生应了解他汀类药物治疗（包括瑞舒伐他汀）期间可能发生的不良认知反应。
Memory loss and cognitive impairment have been reported in the literature in association with several 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins), but we found no published case reports associated with rosuvastatin. To our knowledge, this is the first reported case of rosuvastatin-related short-term memory loss. A 53-year-old Caucasian man with hypercholesterolemia experienced memory loss after being treated with rosuvastatin 10 mg/day. He had no other concomitant conditions or drug therapies. After discontinuation of rosuvastatin, the neuropsychiatric adverse reaction resolved gradually, suggesting a probable drug association. During the following year, the patient remained free from neuropsychiatric disturbances. Clinicians should be aware of possible adverse cognitive reactions during statin therapy, including rosuvastatin.